WCG
BCLI

Weaver Consulting Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Weaver Consulting Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-667
Closed -$500 – 200
2023
Q4 		$500 Sell
667
-2,333
-78% -$6.99K ﹤0.01% 195
2023
Q3 		$2.75K Sell
3,000
-393
-12% -$8.94K ﹤0.01% 187
2023
Q2 		$11.7K Buy
3,393
+1,400
+70% +$58K 0.01% 183
2023
Q1 		$43.1K Sell
1,993
-1,574
-44% -$45.7K 0.02% 178
2022
Q4 		$10K Sell
3,567
-1,100
-24% -$41.1K 0.01% 177
2022
Q3 		$20K Buy
+4,667
New +$234K 0.01% 165

Other funds holding BCLI

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Weaver Consulting Group's BCLI Position: Q3 2025 in Review

Weaver Consulting Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 15,623 shares — an estimated $17.5K sold.

Weaver Consulting Group first reported a position in BCLI in Q1 2021 and held it in 18 quarters. The position peaked at $622K in Q4 2021. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • Weaver Consulting Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • Weaver Consulting Group sold 15,623 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $17.5K.
  • Weaver Consulting Group first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2021 and held it in 18 quarters.
  • Weaver Consulting Group's BRAINSTORM CELL THERAPUTC position peaked at $622K in Q4 2021.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Weaver Consulting Group's 13F filing for Q3 2025, filed 12 Nov 2025.